Image Place holder

Rutika Mehta, MD, MPH


Specialty: Medical Oncology
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Focus: Colorectal Cancer , Esophageal Cancer , Gallbladder Cancer , Liver Cancer , Pancreatic Cancer , Small Intestine Cancer , Stomach (Gastric) Cancer , Anal Cancer, Colon Cancer

Dr. Mehta received her MD degree from Topiwala National Medical College, Mumbai, India. She received a Master of Science in Public Health in Epidemiology at St. Louis University School of Public Health at Indiana University, followed by a Master of Public Health in Epidemiology at Purdue University, Indianapolis Indiana. Dr. Mehta also completed a one-year Research Fellowship in Pathology at Indiana University School of Medicine, Translational Genomics Core. She completed her Internal Medicine Residency at Johns Hopkins University/Sinai Hospital of Baltimore, Maryland. Dr. Mehta recently completed a Hematology/Oncology Fellowship at the University of Buffalo, Roswell Park Cancer Institute, Buffalo, New York. Dr. Mehta’s clinical interests are a spectrum of gastrointestinal cancers including esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers, both early stages and advanced stages. Dr. Mehta’s research interests are primarily esophageal/gastric cancers and colon cancer. She is interested in bringing basic research to the clinic by developing innovative clinical trials for patients.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of Buffalo/Roswell Park Cancer Institute - Hematology Oncology

Residency:

  • Johns Hopkins University/Sinai Hospital of Baltimore - Internal Medicine

Medical School:

  • Topiwala National Medical College, Mumbai, India - MBBS
Participating Trials

CLINICAL TRIAL 19883
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma (GEA)
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Oxaliplatin (); ZW25 (); eloxatin (Oxaliplatin); leucovorin ()
Open

CLINICAL TRIAL 19945
A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 "The FUZE Clinical Trial"
Condition: Genitourinary
Intervention: Debio 1347 ()
Open

CLINICAL TRIAL 20019
Ramucirumab Plus Irinotecan in Patients with Previously Treated Advanced Gastric or Gastro-Esophageal Junction Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: CPT-11 (irinotecan); Camptosar (irinotecan); IMC-1121B (Ramucirumab); Ramucirumab (); irinotecan ()
Open

CLINICAL TRIAL 20166
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients with Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) high Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: Niraparib ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FCL, Chasen B, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MHG, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. 2019 Oct. Pubmedid: 31670288.
  • Saeed SM, Fontaine JP, Dam AN, Hoffe SE, Cameron M, Frakes J, Mehta R, Gurd E, Pimiento JM. Is Preoperative G-Tube Use Safe for Esophageal Cancer Patients?. J Am Coll Nutr. 2019 Aug;1-6. Pubmedid: 31397638.
  • Mehta R, Almhanna K. Predictive markers in gastric cancer immunotherapy treatment-are we there yet?. Transl Gastroenterol Hepatol. 2019.4:4. Pubmedid: 30854491. Pmcid: PMC6378244.
  • Mehta R, Shah A, Almhanna K. Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. Onco Targets Ther. 2018 Oct.11:6525-6537. Pubmedid: 30323626. Pmcid: PMC6177372.
  • Jasra S, Opyrchal M, Norton L, Mehta R. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. Clin Breast Cancer. 2017 Feb;17(1):e37-e41. Pubmedid: 27665021.
  • Miller K, Mehta R, Abraham J, Opneja A, Jain RK. Patterns of Long-term Cancer Survivorship Care in a National Cancer Institute-Designated Comprehensive Cancer Center. Am J Clin Oncol. 2017 Dec;40(6):639-643. Pubmedid: 26359697.
  • Miller KD, Pandey M, Jain R, Mehta R. Cancer Survivorship and Models of Survivorship Care: A Review. Am J Clin Oncol. 2015 Dec;38(6):627-633. Pubmedid: 25635609.
  • Gökmen-Polar Y, Goswami CP, Toroni RA, Sanders KL, Mehta R, Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW. Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. J Cancer. 2014 Aug;5(8):633-645. Pubmedid: 25157274. Pmcid: PMC4142325.
  • Vladislav T, Jain RK, Alvarez R, Mehta RJ, Gökmen-Polar Y, Kesler KA, Henley JD, Loehrer PJ, Badve S. Extrathoracic metastases of thymic origin: a review of 35 cases. Mod Pathol. 2012 Mar;25(3):370-377. Pubmedid: 22080058.
  • Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):881-890. Pubmedid: 21503684.
  • Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat. 2012 Dec;136(3):673-682. Pubmedid: 23085766.
  • Mehta R, Jain RK, Badve S. Personalized medicine: the road ahead. Clin Breast Cancer. 2011 Mar;11(1):20-26. Pubmedid: 21421518.
  • Patel JB, Appaiah HN, Burnett RM, Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S, Steeg P, Liu Y, Nakshatri H. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 2011 Mar;30(11):1290-1301. Pubmedid: 21057539.
  • Jain RK, Mehta R, Dimitrov R, Larsson LG, Musto PM, Hodges KB, Ulbright TM, Hattab EM, Agaram N, Idrees MT, Badve S. Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol. 2011 Jul;24(7):917-923. Pubmedid: 21532546.
  • Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, Shah K. PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci. 2011 Aug;124(Pt 16):2711-2722. Pubmedid: 21807936.
  • Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS. High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology. 2011 Apr;58(5):766-772. Pubmedid: 21401706.
  • Appaiah H, Bhat-Nakshatri P, Mehta R, Thorat M, Badve S, Nakshatri H. ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Cancer Biol Ther. 2010 Sep;10(6):600-614. Pubmedid: 20603605. Pmcid: PMC3040950.
  • McCune K, Mehta R, Thorat MA, Badve S, Nakshatri H. Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. Oncol Rep. 2010 Nov;24(5):1233-1239. Pubmedid: 20878115. Pmcid: PMC2948410.
  • Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW, Badve S. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat. 2010 Nov;124(2):327-335. Pubmedid: 20099025.
  • Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, Parry S, Ashworth A, Badve S, Reis-Filho JS. Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol. 2010 Jul.23(7):951-960. Pubmedid: 20453835.
  • Jain RK, Mehta RJ, Henley JD, Kesler KA, Loehrer PJ, Badve S. WHO types A and AB thymomas: not always benign. Mod Pathol. 2010 Dec;23(12):1641-1649. Pubmedid: 20834239.
  • Jain RK, Mehta R, Badve S. Conjunctival squamous cell carcinoma due to ocular prostheses: a case report and review of literature. Pathol Oncol Res. 2010 Dec;16(4):609-612. Pubmedid: 20376710.
  • Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol. 2010 Aug;63(8):744-747. Pubmedid: 20702478.
  • Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2010 Aug;123(1):97-108. Pubmedid: 19911270.